<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313649</url>
  </required_header>
  <id_info>
    <org_study_id>LE2</org_study_id>
    <nct_id>NCT02313649</nct_id>
  </id_info>
  <brief_title>ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B</brief_title>
  <official_title>Evaluation of ShearWave™ Elastography Performances for the Non-Invasive Assessment of Liver Fibrosis in Chinese Patients With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SuperSonic Imagine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SuperSonic Imagine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how liver stiffness measurements made with ShearWave™ Elastography&#xD;
      (SWE) correspond with a biopsy result (currently the gold standard). The population that will&#xD;
      be evaluated are Chinese patients infected with the Hepatitis B virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B is becoming increasingly common. The liver becomes stiffer and this is called&#xD;
      fibrosis. A non-invasive method to accurately stage fibrosis is necessary in order to begin&#xD;
      the correct treatment. Currently, liver biopsy is used to do this, but there are many&#xD;
      disadvantages with this technique.&#xD;
&#xD;
      ShearWave Elastography (SWE), available on the ultrasound machine Aixplorer®, is a&#xD;
      non-invasive method to evaluate liver fibrosis.&#xD;
&#xD;
      This study will evaluate how liver stiffness measurements made with SWE correspond with a&#xD;
      biopsy result (currently the gold standard).&#xD;
&#xD;
      The sensitivity, specificity, positive predictive value and negative predictive value of&#xD;
      liver stiffness measurements with Aixplorer to evaluate the different stages of fibrosis will&#xD;
      be analyzed.&#xD;
&#xD;
      Liver stiffness measurement made by the Aixplorer will also be compared to blood markers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Areas under the ROC curves for the ability of SWE measurements to predict at least significant fibrosis (Metavir F≥2), at least severe fibrosis (Metavir F≥3), and liver cirrhosis (Metavir F=4).</measure>
    <time_frame>Within 12 months of the study start date</time_frame>
    <description>This will be determined by histological examination of liver biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, positive and negative predictive values of SWE to predict at least significant fibrosis (Metavir F≥2), at least severe fibrosis (Metavir F≥3), and liver cirrhosis (Metavir F=4).</measure>
    <time_frame>Within 12 months of the study start date</time_frame>
    <description>This will be determined by histological examination of liver biopsy</description>
  </secondary_outcome>
  <enrollment type="Actual">447</enrollment>
  <condition>Liver Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients with chronic viral hepatitis B admitted for the realization of an&#xD;
        intercostal liver biopsy in defined investigator centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing a liver ultrasound exam due to confirmed Hepatitis B infection ,&#xD;
&#xD;
          -  Patients having reached the age of majority in China,&#xD;
&#xD;
          -  Patients with a liver biopsy for histological evaluation of liver fibrosis, performed&#xD;
             within 3 months after the SWE measurement date, and having the recommended quality&#xD;
             criterion:&#xD;
&#xD;
               -  minimal length of biopsy samples of 15 mm, stored in paraffin&#xD;
&#xD;
               -  Minimal number of portal tracts of 6 per biopsy samples&#xD;
&#xD;
          -  Patients of Chinese ethnic origin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient presenting with combined etiologies of chronic liver diseases, including&#xD;
             non-Hepatitis B viral infection（Hepatitis A, C, D, E, chronic alcoholic liver disease,&#xD;
             hemochromatosis, autoimmune hepatitis, etc)&#xD;
&#xD;
          -  History of antiviral therapy at any time&#xD;
&#xD;
          -  Any patient presenting with a co-infection of HIV&#xD;
&#xD;
          -  Any patient presenting with combined liver malignant tumor&#xD;
&#xD;
          -  Previous liver transplantation&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Any patient with combined hepatic congestive condition such as Budd Chiari Syndrome,&#xD;
             congestive heart failure, chronic constrictive pericarditis…&#xD;
&#xD;
          -  Any patient combined with intrahepatic cholestasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Liberation Army General（301）Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>People's Liberation Army General（301）Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GuangZhou 8th People's Hospital</name>
      <address>
        <city>GuangZhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated Hospital, Haerbin Medical University</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated Hospital, ZheJiang University</name>
      <address>
        <city>HangZhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YunNan Province Second People's Hospital</name>
      <address>
        <city>KunMing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, Lanzhou University</name>
      <address>
        <city>LanZhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial Hospital</name>
      <address>
        <city>NanJing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai 1st People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of Chinese Medical University</name>
      <address>
        <city>ShenYang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated Hospital, XiAn Transportation University</name>
      <address>
        <city>XiAn</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>XiAn</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isolation Hospital, HeNan Province</name>
      <address>
        <city>ZhengZhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>fibrosis</keyword>
  <keyword>elastography</keyword>
  <keyword>ShearWave Elastography</keyword>
  <keyword>ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

